Business
Alector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial
Treatment with AL001 (latozinemab) demonstrated target engagement and resulted in increases in progranulin levels in all patients FTD-C9orf72 patients treated
About this update from Alector, Inc.
[{"type":"text","content":"Treatment with AL001 (latozinemab) demonstrated target engagement and resulted in increases in progranulin levels in all patients FTD-C9orf72 patients treated with latozinemab demonstrated a trend toward a delay in disease progression relative to the ALLFTD matched control cohort First clinical dataset in an indication where latozinemab elevated progranulin above physiological levels Company to host webcast to review results today at 8:30 a.m. ET SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, presented results from the INFRONT-2 Phase 2 clinical trial of AL001 (latozinemab) in frontotemporal dementia patients (FTD) with a C9orf72 genetic mutation (FTD-C9orf72) at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders taking place virtually and in person in Barcelona, Spain. Latozinemab is a potential first-in-class monoclonal antibody designed to elevate progranulin, a key regulator of immune activity and lysosomal health in the brain. FTD is a rare and rapidly progressing neurodegenerative disease that is the most common form of dementia for people under the age of 60. In 2021, Alector presented results showing that latozinemab elevated progranulin levels in a cohort of symptomatic carriers of the progranulin mutation causative of FTD (FTD-GRN) patients for the duration of treatment, and as compared to matched controls, showed associated changes in exploratory biomarkers and a trend toward a delay in annual disease progression. Today’s data from the FTD-C9orf72 cohort build upon the results observed in the Company’s studies to date in FTD-GRN patients. The results presented include 12-month data from up to 10 symptomatic FTD-C9orf72 patients treated with 60 mg/kg of latozinemab every four weeks in an open-label study designed to primarily assess the safety and tolerability of chronic dosing. The study also includes exploratory clinical outcomes assessments and biomarkers. Highlights from the presentation included the following observations: Latozinemab was generally well tolerated when administered monthly for a year or more, consistent with other study cohorts.Latozinemab elevated progranulin in both plasma and cerebrospinal fluid (CSF) in FTD-C9orf72 pa...